NCT06485986 Frontosubthalamic Networks in Parkinson's Disease.
| NCT ID | NCT06485986 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Oxford |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-06-01 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this experimental study with is to understand the underlying mechanisms behind the increase in impulsivity seen in some patients that undergo deep brain stimulation of the subthalamic nucleus for Parkinson's Disease. The main questions it aims to answer are: What are the distributed network effects of deep brain stimulation to the subthalamic nucleus? How does this correlate with increased impulsivity? Can alternative stimulation settings be used to minimize these? Participants will complete decision-making tasks whilst their deep brain stimulation devices are turned on and off with simultaneous magnetoencephalography recordings (a type of non-invasive brain scan that measures brain activity in real-time)
Eligibility Criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged 18 years or above. * Diagnosed with Parkinson's disease who have required implanted STN electrodes for DBS in addition to their dopamine replacement therapy. * Diagnosed with or without (control group) impulse control disorders since the diagnosis of Parkinson's Disease. * Participant willing and able to sit in the MEG scanner and follow instructions. * Participant willing and able to delay their morning dose of dopamine replacement therapy for up to four hours (180 minutes experimental time + journey time). Exclusion Criteria: * Patients with extreme language barrier that cannot understand the purpose or instructions of the study despite the use of an interpreter. * Other implanted medical devices that may cause artefacts during MEG recordings. * Participants with a history of co-morbid neurological disorders. * Participant enrolled onto another clinical trial related to a neurological disorder (including Parkinson's disease) that may interfere with the results of this study. * Participants who are unable to sit still in a MEG scanner for the duration of this experiment e.g. patients with chronic pain or osteoarthritis. This will be assessed with their primary clinician
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06485986 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06485986 currently recruiting?
Yes, NCT06485986 is actively recruiting participants. Contact the research team at john.eraifej@ndcn.ox.ac.uk for enrollment information.
Where is the NCT06485986 trial being conducted?
This trial is being conducted at Oxford, United Kingdom.
Who is sponsoring the NCT06485986 clinical trial?
NCT06485986 is sponsored by University of Oxford. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.